Press Releases Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-08 EDT			5-day change	1st Jan Change
2.76 ^USD	-5.15%		-5.48%	-14.02%

04-26	Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development	MT
04-26	Allogene Therapeutics Receives Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update	05-06	GL
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma	04-26	GL
Allogene Therapeutics Announces Q2 Investor Conference Participation	04-09	GL
Allogene Therapeutics: Q4 Earnings Snapshot	03-14	AQ
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update	03-14	GL
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease	03-12	GL
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update	03-05	GL
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference	02-28	GL
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference	02-28	AQ
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia	02-19	AQ
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia	02-16	GL
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences	01-16	GL
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma	01-04	GL
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma	01-04	GL
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma	01-04	AQ
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference	01-03	AQ
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference	01-03	GL
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology	12-11	AQ
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology	12-09	AQ
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology	12-09	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Press Releases

Filters